5 results about "Protein S level" patented technology

The present application belongs to the technical field of biomedicine, and provides a pharmaceutical composition for inhibiting NFKBIZ gene expression, and a use. The present application designs a double-stranded nucleic acid molecule capable of targeting and regulating NFKBIZ gene expression. By means of verifying the gene regulation efficiency of nucleic acid molecules, multiple nucleic acid molecules capable of inhibiting NFKBIZ gene expression are obtained from screening, and efficient inhibition of IκB-ζ protein expression is achieved at the protein level. In addition, the present application verifies a use of a pharmaceutical composition formed by the conjugation of the described nucleic acid molecules and targeting ligand molecules in ophthalmic diseases. The pharmaceutical composition can solve the problems with existing small molecule immunomodulatory drugs of low delivery efficiency and poor therapeutic effect, providing small nucleic acid drugs having tissue-targeted delivery functions, and has the advantages of long duration of efficacy and low side effects. In addition, the pharmaceutical composition has simple ingredients, is easy to synthesize, and has good prospects for translational applications.

The present invention relates to a method for specifically degrading KRAS mutant (G12V) by treating a cell line expressing KRAS mutant (G12V) with a complex of a RAS binder that specifically binds to KRAS mutant (G12V) and an E3 ligase (E3 ligase) NEDD4 HECT, and a composition for use in the method. It can be confirmed that the method developed in the present invention, when treating a cell line expressing KRAS wild type, KRAS wild type is not degraded, in a KRAS mutant (G12V) cell line, the protein level is decreased, the ERK activity is inhibited, and the proliferation, penetration of cancer cells related to KRAS mutant (G12V) is inhibited.

The invention provides a method of detecting or predicting a relapse of multiple sclerosis in an individual having a form of multiple sclerosis, comprising: (a) providing a blood sample of the individual; (b) testing the blood sample to determine a protein activity or protein level, wherein the protein is Factor VIII, von Willebrand Factor, or Protein C; and (c) detecting or predicting a relapse of multiple sclerosis in the individual if the protein activity or protein level is elevated compared to the protein activity or protein level in an individual not having the form of multiple sclerosis and the patient's own baseline value. The invention also provides a method of treating an individual having multiple sclerosis who is experiencing a relapse or is predicted to experience a relapse, comprising treating the individual by administering a dose of a steroid or an anticoagulant compound effective to reduce symptoms of multiple sclerosis.

This specification provides a method for providing information on metachronous recurrence of gastric cancer, the method comprising: measuring the mRNA or protein level of at least one marker gene among CD8, CD4 and PD-L1 in a biological sample isolated from an individual; and determining the likelihood of metachronous gastric cancer recurrence in an individual based on the measured mRNA or protein level of the marker gene.